Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5546534 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL12858416 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL14215490 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL7829903 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL9295329 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL9767712 | 1.00 | CA2 (0.35) | CA2MGAMCA1GAASI | |
| SCHEMBL3859689 | 0.94 | GBA1 (0.42) | CA2MGAMCA1GAASI | |
| SCHEMBL2951506 | 0.94 | GBA1 (0.42) | CA2MGAMCA1GAASI | |
| SCHEMBL17827504 | 0.90 | MGAM (0.36) | CA2MGAMCA1GAASI | |
| SCHEMBL3867661 | 0.90 | MGAM (0.36) | CA2MGAMCA1GAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | WARATAH PHARMACEUTICALS INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| WO-2007119108-A2 | INOSITOL DERIVATIVES AND THEIR USES IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| WO-2007041855-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERISED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
| EP-0738153-A4 | SYNTHETIC INSULIN MIMETIC SUBSTANCES | UNIV VIRGINIA (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6093697-A | Synthetic insulin mimetic substances | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0753016-A4 | IMMUNOASSAY FOR INOSITOLS | UNIV VIRGINIA (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5652221-A | Method of treating defective glucose metabolism using synthetic insulin substances | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0753016-A1 | IMMUNOASSAY FOR INOSITOLS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0738153-A1 | SYNTHETIC INSULIN MIMETIC SUBSTANCES | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5525526-A | Immunoassay for inositols | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1996014075-A1 | SYNTHETIC INSULIN MIMETIC SUBSTANCES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995021196-A1 | IMMUNOASSAY FOR INOSITOLS | UNIVERSITY OF VIRGINIA PATENTS FOUNDATION (US) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | CA2 1937/4885MGAM 2322/4885CA1 2317/4885 |
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | CA2 2496/4885MGAM 2539/4885CA1 723/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | CA2 2291/4885MGAM 489/4885CA1 3771/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | CA2 2349/4885MGAM 466/4885CA1 3722/4885 |
| US-20100105631-A1 | Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence | SCLY, SMOX, SMS | CA2 1937/4885MGAM 2322/4885CA1 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.